FrancophonIA/ELRC3.0 huggingface dataset:
English: Metformin Hydrochloride 850mg Tablet, Canagliflozin 150mg Tablet
Estonian: Metformiinvesinikkloriid 850mg Tablett, Kanagliflosiin 150mg Tablett
English: Metformin Lindopharm Metformin Hydrochloride 850mg Tablet
Estonian: Metformin Lindopharm Metformiinvesinikkloriid 850mg Tablett Õhukese polümeerikattega tablett
English: Metformin-Ratiopharm Metformin Hydrochloride 500mg Tablet
Estonian: Metformin-Ratiopharm Metformiinvesinikkloriid 500mg Tablett Õhukese polümeerikattega tablett
English: Metformin-Ratiopharm Metformin Hydrochloride 850mg Tablet
Estonian: Metformin-Ratiopharm Metformiinvesinikkloriid 850mg Tablett Õhukese polümeerikattega tablett
English: Metformin Hydrochloride 500mg Film Film-Coated Tablet
Estonian: Metformiinvesinikkloriid 500mg Tablett Kaetud tablett
English: Germany Denk Pharma Gmbh & Co. Kg Metfo
Estonian: Denk Pharma Gmbh & Co.
English: Metformin Hydrochloride 850mg Tablet, Canagliflozin 50mg Tablet
Estonian: Metformiinvesinikkloriid 850mg Tablett, Kanagliflosiin 50mg Tablett
English: Metformin Relonchem Metformin Hydrochloride 850mg Tablet
Estonian: Metformin Relonchem Metformiinvesinikkloriid 850mg Tablett Õhukese polümeerikattega tablett
English: Metformin Hydrochloride 1000mg Tablet, Saxagliptin 2.5mg Tablet
Estonian: Metformiinvesinikkloriid 1000mg Tablett, Saksagliptiin 2.5mg Tablett
English: Metformine Hcl Ratiopharm Metformin Hydrochloride 1000mg Tablet Film-Coated Tablet
Estonian: Metformine Hcl Ratiopharm Metformiinvesinikkloriid 1000mg Tablett Õhukese polümeerikattega tablett
English: Metformin Ratiopharm Metformin Hydrochloride 850mg Tablet
Estonian: Metformin Ratiopharm Metformiinvesinikkloriid 850mg Tablett Õhukese polümeerikattega tablett
English: Metformin Hcl Plus Pharmacie Metformin Hydrochloride 1000mg Tablet Film-Coated Tablet
Estonian: Metformine Mylan Pharma Metformiinvesinikkloriid 1000mg Tablett Õhukese polümeerikattega tablett
English: Metformin Ratiopharm Metformin Hydrochloride 500mg Tablet
Estonian: Metformin Ratiopharm Metformiinvesinikkloriid 500mg Tablett Õhukese polümeerikattega tablett
English: Metformine Hcl Ratiopharm Metformin Hydrochloride 500mg Tablet
Estonian: Metformine Hcl Ratiopharm Metformiinvesinikkloriid 500mg Tablett Õhukese polümeerikattega tablett
English: Metformin Glenmark
Estonian: Glenmark Arzneimittel Gmbh Metformin Glenmark
English: Metformin Ratiopharm Metformin Hydrochloride 1000mg Tablet Film-Coated Tablet
Estonian: Metformin Ratiopharm Metformiinvesinikkloriid 1000mg Tablett Õhukese polümeerikattega tablett
English: Metformina Ratiopharm Metformin Hydrochloride 1000mg Tablet Film-Coated Tablet
Estonian: Metformina Ratiopharm Metformiinvesinikkloriid 1000mg Tablett Õhukese polümeerikattega tablett
English: Metformina Ratiopharm Metformin Hydrochloride 500mg Tablet
Estonian: Metformina Ratiopharm Metformiinvesinikkloriid 500mg Tablett Õhukese polümeerikattega tablett
English: Metformina Ratiopharm Metformin Hydrochloride 850mg Tablet
Estonian: Metformina Ratiopharm Metformiinvesinikkloriid 850mg Tablett Õhukese polümeerikattega tablett
English: Metformin Hydrochloride 850mg Tablet, Saxagliptin 2.5mg Tablet
Estonian: Metformiinvesinikkloriid 850mg Tablett, Saksagliptiin 2.5mg Tablett
English: Some patients were treated for up to five and a half years.
Estonian: Osa patsiente raviti kuni viis ja pool aastat.
English: It is available as capsules (100 mg).
Estonian: Seda turustatakse kapslitena (100 mg).
English: • Gaucher disease;
Estonian: • Gaucher' tõbi;
English: Zavesca is intended for long-term use.
Estonian: Zavesca on ette nähtud pikaajaliseks kasutamiseks.
English: The main part of the study lasted for a year, but 13 patients carried on receiving the medicine for a further two years.
Estonian: Uuringu põhiosa kestis üks aasta, kuid 13 patsienti said ravimit veel kaks aastat.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Zavesca on 20 November 2002.
Estonian: Euroopa Komisjon andis Zavesca müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 20. novembril
English: There were also small improvements in blood counts: on average, the levels of haemoglobin increased by 0.26 g per decilitre and platelet counts increased by 8.29 million per millilitre.
Estonian: Ka verenäitajad paranesid mõnevõrra: hemoglobiini sisaldus suurenes keskmiselt 0,26 g/dl võrra ja trombotsüütide sisaldus suurenes 8,29 miljoni võrra milliliitri kohta.
English: As the company had supplied the additional information requested, the exceptional circumstances ended on 23 August 2012.
Estonian: Et ettevõte esitas nõutud lisateabe, tühistati 23. augustil 2012 müügiloa erandkorras väljastatus.
English: EPAR summary for the public miglustat
Estonian: Kokkuvõte üldsusele miglustaat
English: The company also presented the results of a survey of 66 patients treated with Zavesca.
Estonian: Ettevõte esitas samuti Zavescaga ravitud 66 patsiendi uuringu tulemused.
English: Zavesca is used to treat the following patients:
Estonian: Zavescat kasutatakse järgmiste patsientide ravis:
English: The summaries of the opinions of the Committee for Orphan Medicinal Products for Zavesca on the Agency's website ema.europa.eu/Find medicine/Human medicines/Rare disease designations:
Estonian: Harvikravimite komitee arvamuste kokkuvõtted Zavesca kohta on ameti veebilehel aadressil ema.europa.eu/Find medicine/Human medicines/Rare disease designations:
English: The full EPAR for Zavesca can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Zavesca kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Zavesca was originally authorised under ‘exceptional circumstances' because, as the diseases are rare, limited information was available at the time of approval.
Estonian: Esialgu kiideti Zavesca heaks erandkorras, sest haigus esineb harva ja ravimi heakskiitmise ajal ei olnud piisavalt teavet.
English: The main measure of effectiveness was the change in the speed at which the patients made saccadic horizontal eye movements after a year, but the study also looked at other neurological symptoms such as the patients' ability to swallow and their intellectual function.
Estonian: Efektiivsuse põhinäitaja oli muutus patsiendi sakaadiliste horisontaalsete silmaliigutuste kiiruses pärast üheaastast ravi, kuid vaadeldi ka teisi neuroloogilisi sümptomeid, nagu patsiendi neelamisvõime ja vaimsed võimed.
English: What is the risk associated with Zavesca?
Estonian: Mis riskid Zavescaga kaasnevad?
English: The CHMP decided that Zavesca's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Zavesca kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: For Niemann-Pick type C disease, it is two capsules three times a day for patients aged 12 years and over; in younger patients, the dose depends on their weight and height.
Estonian: C-tüüpi Niemanni-Picki tõve korral on vähemalt 12-aastaste patsientide algannus kaks kapslit kolm korda ööpäevas, nooremate patsientide annus oleneb nende kaalust ja pikkusest.
English: What is Zavesca?
Estonian: Mis on Zavesca?
English: Why has Zavesca been approved?
Estonian: Miks Zavesca heaks kiideti?
English: Because the number of patients with these diseases is low, they are considered ‘rare', and Zavesca was designated an ‘orphan medicine' (a medicine used in rare diseases) on 18 October 2000 for type 1 Gaucher disease and on 16 February 2006 for Niemann-Pick type C disease.
Estonian: Et nende haigustega patsiente on vähe ja neid haigusi esineb harva, nimetati Zavesca 18. oktoobril 2000 I tüüpi Gaucher' tõve ja 16. veebruaril 2006 C-tüüpi Niemanni-Picki tõve harvikravimiks.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zavesca.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: • Niemann-Pick type C disease.
Estonian: • C-tüüpi Niemanni-Picki tõbi.
English: These include loss of co-ordination, problems with ‘saccadic' (rapid) eye movements that can lead to impaired vision, delayed development, difficulty swallowing, decreased muscle tone, fits and learning difficulties.
Estonian: Nende hulka kuuluvad koordinatsioonivõime kadumine, sakaadiliste (aktiivse vaatlemisega seotud kiirete) silmaliigutuste häired, mis võivad halvendada nägemist, arengupeetus, neelamisraskused, lihastoonuse vähenemine, krambid ja õppimisraskused.
English: Zavesca is used to treat the neurological symptoms of the disease (symptoms affecting the brain and nerves).
Estonian: Zavescaga ravitakse haiguse neuroloogilisi (peaaju ja närve mõjutavaid) sümptomeid.
English: For the full list of all side effects reported with Zavesca, see the package leaflet.
Estonian: Zavesca kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: For more information about treatment with Zavesca, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Zavescaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: For Niemann-Pick type C disease, Zavesca was studied in one main study involving 31 patients, 12 of whom were less than 12 years old.
Estonian: Zavesca efektiivsust C-tüüpi Niemanni-Picki tõve korral uuriti ühes põhiuuringus, milles osales 31 patsienti, kellest 12 olid alla 12-aastased.
English: • adults (aged 18 years and above) with mild to moderate type 1 Gaucher disease.
Estonian: • vähemalt 18-aastased täiskasvanud kerge või mõõduka I tüüpi Gaucher' tõvega.
English: Zavesca is a medicine that contains the active substance miglustat.
Estonian: Zavesca on ravim, mis sisaldab toimeainena miglustaati.
English: Zavesca must not be used in people who are hypersensitive (allergic) to miglustat or any of the other ingredients.
Estonian: Zavescat ei tohi kasutada patsiendid, kes on miglustaadi või ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: This is expected to slow down or prevent the development of the symptoms of type 1 Gaucher disease and to reduce the symptoms of Niemann-Pick type C disease.
Estonian: Eeldatavasti aeglustab või ennetab miglustaat sel viisil I tüüpi Gaucher' tõve sümptomite teket ja vähendab C-tüüpi Niemanni-Picki tõve sümptomeid.
English: Zavesca is used in patients who cannot receive the standard treatment of enzyme replacement therapy (ERT);
Estonian: Zavescat kasutatakse patsientidel, keda ei saa ravida standardse ensüümiasendusraviga;
English: The study looked at the effect of Zavesca on the size of the liver and spleen, and at blood counts, such as the levels of haemoglobin (a protein found in red blood cells that carries oxygen around the body) and platelets (components that help the blood to clot).
Estonian: Uuringus jälgiti Zavesca toimet maksa ja põrna suurusele ning verenäitajatele, nagu hemoglobiini (vere punaliblede valk, mis kannab hapnikku organismis laiali) ja trombotsüütide (vereliistakud ehk hüübimist soodustavad vererakud) sisaldus.
English: The recommended starting dose for type 1 Gaucher disease is one capsule three times a day.
Estonian: Soovitatav algannus I tüüpi Gaucher' tõve korral on üks kapsel kolm korda ööpäevas.
English: In the study of Niemann-Pick type C disease, the improvement in eye movements was similar in patients treated with and without Zavesca.
Estonian: C-tüüpi Niemanni-Picki tõve uuringus oli silmaliigutuste paranemine Zavescaga ravitud patsientidel samalaadne kui neil, kes Zavesca ravi ei saanud.
English: Patients with this disease lack an enzyme called glucocerebrosidase, which results in a glycosphingolipid called glucosylceramide building up in different parts of the body, such as the spleen, liver and bones.
Estonian: Selle haigusega patsientidel on ensüümi glükotserebrosidaasi vaegus, mistõttu koguneb eri kehaosadesse, näiteks põrna, maksa ja luudesse, glükosüültseramiidiks nimetatavat glükosfingolipiidi.
English: The benefits of Zavesca were maintained over three years of continuous treatment.
Estonian: Zavesca kasulikkus säilis enam kui kolm aastat kestnud ravis.
English: The most common side effects with Zavesca (seen in more than 1 patient in 10) are weight loss, decreased appetite, tremor (shaking), diarrhoea, flatulence (gas) and abdominal pain (stomach ache).
Estonian: Zavesca kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on kehakaalu vähenemine, söögiisu vähenemine, värin, kõhulahtisus, kõhupuhitus ja kõhuvalu.
English: This document is a summary of the European Public Assessment Report (EPAR) for Zavesca.
Estonian: See on ravimi Zavesca Euroopa avaliku hindamisaruande kokkuvõte.
English: Both diseases cause a build-up of fatty substances called glycosphingolipids in the body.
Estonian: Mõlemad haigused põhjustavad rasvainete glükosfingolipiidide teket organismis.
English: The study compared the effects of adding Zavesca to standard care with the effects of standard care alone.
Estonian: Uuringus võrreldi Zavesca ja tavalise ravi koosmõju tavalise ravi mõjuga.
English: Zavesca is used to treat two inherited diseases that affect the way the body handles fats.
Estonian: Zavescaga ravitakse kaht harvaesinevat pärilikku haigust, mis mõjutavad rasvade ainevahetust organismis.
English: How is Zavesca used?
Estonian: Kuidas Zavescat kasutatakse?
English: A lower dose should be used in patients with reduced kidney function.
Estonian: Vähenenud neerutalitlusega patsientidel peab kasutama väiksemat annust.
English: For further information, see the summary of product characteristics (also part of the EPAR).
Estonian: Üksikasjalik teave on ravimi omaduste kokkuvõttes (samuti Euroopa avaliku hindamisaruande osa).
English: The survey showed that Zavesca led to a stabilisation or a decrease in the rate at which symptoms got worse in about three-quarters of the patients.
Estonian: Uuring näitas, et ligikaudu kolmel neljandikul patsientidest stabiliseeris Zavesca sümptomeid või vähendas nende progresseerumise kiirust.
English: What benefit has Zavesca shown during the studies?
Estonian: Milles seisneb uuringute põhjal Zavesca kasulikkus?
English: This enzyme is involved in the first step of the production of glycosphingolipids.
Estonian: See ensüüm osaleb glükosfingolipiidide tekke esimesel etapil.
English: In the study of type 1 Gaucher disease, there were moderate reductions in the size of the liver (12% reduction) and the spleen (19% reduction) after a year.
Estonian: I-tüüpi Gaucher' tõvega patsientide uuringus vähenes maksa ja põrna suurus ühe aasta möödudes veidi, vastavalt 12% ja 19%.
English: What is Zavesca used for?
Estonian: Milleks Zavescat kasutatakse?
English: By preventing the enzyme from working, miglustat can reduce the production of glycosphingolipids in cells.
Estonian: Ensüümi toime pärssimisega vähendab miglustaat glükosfingolipiidide teket rakkudes.
English: However, there were signs of improvement in swallowing ability and intellectual function in the patients treated with Zavesca.
Estonian: Zavesca ravi saanud patsientidel täheldati siiski neelamisvõime ja vaimsete võimete paranemist.
English: For type 1 Gaucher disease, Zavesca was investigated in one main study involving 28 adults with mild to moderate disease who were unable or unwilling to receive ERT.
Estonian: Zavesca efektiivsust I tüüpi kerge kuni mõõduka Gaucher' tõve ravis uuriti ühes põhiuuringus 28 patsiendil, kellele ensüümasendusravi ei saanud teha või kes seda ei soovinud.
English: The active substance in Zavesca, miglustat, prevents an enzyme called glucosylceramide synthase from working.
Estonian: Zavesca toimeaine miglustaat pärsib ensüümi glükosüültseramiidsüntaasi toimet.
English: Other information about Zavesca:
Estonian: Muu teave Zavesca kohta
English: The medicine can only be obtained with a prescription.
Estonian: Zavesca on retseptiravim.
English: Treatment with Zavesca should be started and monitored by doctors who are experienced in the management of Gaucher or Niemann-Pick type C disease.
Estonian: Ravi Zavescaga tohib alustada üksnes Gaucher' tõve või C-tüüpi Niemanni-Picki tõve ravis kogenud arst ning ravi peab toimuma tema järelevalve all.
English: The dose should also be reduced temporarily in patients who develop diarrhoea.
Estonian: Patsientidel, kellel tekib kõhulahtisus, peab annust ajutiselt vähendama.
English: • patients of all ages with Niemann-Pick type C disease, a potentially fatal disease in which glycosphingolipids build up within cells in the brain and elsewhere in the body.
Estonian: See võib olla surmav haigus, mille korral patsientidel ladestub ajurakkudesse ja mujale organismi glükosfingolipiide.
English: How does Zavesca work?
Estonian: Kuidas Zavesca toimib?
English: The European Commission issued a decision on 22 August 2016.
Estonian: Euroopa Komisjon tegi otsuse 22. augustil 2016.
English: The procedure was concluded and on 11 July 2014 the European Commission adopted a Decision1.
Estonian: Menetlus lõpetati ja 11. juulil 2014 tegi Euroopa Komisjon otsuse
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom22 August 2016
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom22.
English: Outcome of a referral procedure under Article 35 of Directive 2001/82/EC (EMEA/V/A/110)
Estonian: Direktiivi 2001/82/EÜ artikli 35 kohase esildismenetluse (EMEA/V/A/110) tulemused
English: The full changes made to the product information for powders for use in the drinking water are detailed in Annex III of the CVMP opinion on the 'All documents' tab.
Estonian: Täielik ülevaade joogiveega manustatavate pulbrite ravimiteabe muudatustest on veterinaarravimite komitee arvamuse III lisa jaotises „Kõik dokumendid“.
English: What are lincomycin and spectinomycin?
Estonian: Mis on linkomütsiin ja spektinomütsiin?
English: Commission Decision concerning, in the framework of Article 34 of Directive 2001/82/EC of the European Parliament and of the Council, the marketing authorisations for “Linco-Spectin 100 and its associated names”, veterinary medicinal products which contain the active substances “Lincomycin and spectinomycin” ((2014)5053 of 11/07/2014) http://ec.europa.eu/health/documents/community-register/html/vo25233.htm
Estonian: Komisjoni otsus, mis käsitleb Euroopa Parlamendi ja nõukogu direktiivi 2001/82/EÜ artikli 34 raames linkomütsiini ja spektinomütsiini sisaldava veterinaarravimi Linco-Spectin 100 ja sarnasete nimetuste müügilube ((2014)5053, 11.7.2014) http://ec.europa.eu/health/documents/community-register/html/vo25233.htm
English: Why were veterinary medicinal products containing a combination of lincomycin and spectinomycin reviewed?
Estonian: Miks vaadati linkomütsiini ja spektinomütsiini kombinatsiooni sisaldavate veterinaarravimite teave läbi?
English: Subsequent to the outcome of the aforementioned Article 34 referral procedure for Linco-Spectin 100, Belgium considered that it is in the interest of the EU to promote effective and rational use of the lincomycin-spectinomycin combination in orally administered veterinary medicinal products, and thereby limit the risk of the development of resistance.
Estonian: Veterinaarravimi Linco-Spectin 100 eespool nimetatud artikli 34 kohase esildismenetluse tulemuste alusel järeldas Belgia, et Euroopa Liidu huvides on soodustada linkomütsiini ja spektinomütsiini kombinatsiooni sisaldavate suukaudsete veterinaarravimite efektiivset ja arukat kasutamist, mis vähendaks ravimiresistentsuse tekke riski.
English: In September 2012 Belgium initiated a referral procedure under Article 34 of Directive 2001/82/EC for Linco-Spectin 100, powder for use in the drinking water for pigs and chickens (EMEA/V/A/088).
Estonian: 2012. aasta septembris algatas Belgia direktiivi 2001/82/EÜ artikli 34 alusel esildismenetluse seoses Linco-Spectin 100 sigadele ja kanadele joogiveega manustatava pulbriga (EMEA/V/A/088).
English: The lincosamides are considered to be bacteriostatic agents.
Estonian: Linkosamiide peetakse bakteriostaatilisteks antibiootikumideks.
English: Therefore, on 5 May 2015, Belgium initiated a procedure under Article 35 of Directive 2001/82/EC for veterinary medicinal products containing a combination of lincomycin and spectinomycin to be administered orally to pigs and/or poultry.
Estonian: Sel põhjusel algatas Belgia 5. mail 2015 direktiivi 2001/82/EÜ artikli 35 kohase menetluse, mis käsitles linkomütsiini ja spektinomütsiini kombinatsiooni sisaldavaid sigade ja/või kodulindude suukaudseid veterinaarravimeid.
English: The CVMP was requested to assess the available data and to review the indications, dosage regimens and withdrawal periods for pigs and poultry in order to ensure consumer safety, efficacious treatment in pigs, chickens and other poultry species, as well as a lower risk of the development of antimicrobial resistance to lincomycin and spectinomycin.
Estonian: Veterinaarravimite komiteel paluti hinnata olemasolevaid andmeid ja läbi vaadata sigadel ja kodulindudel kasutamise näidustused, annustamisskeemid ja keeluajad, et tagada tarbijate ohutus, efektiivne ravi sigadel, kanadel ja teistel kodulindudel ning ühtlasi vähendada linkomütsiini ja spektinomütsiini vastase ravimiresistentsuse tekke riski.
English: Questions and answers on veterinary medicinal products containing a combination of lincomycin and spectinomycin to be administered orally to pigs and/or poultry EMA/462762/2016
Estonian: Teabedokument: linkomütsiini ja spektinomütsiini kombinatsiooni sisaldavad sigade ja/või kodulindude suukaudsed veterinaarravimid EMA/462762/2016
English: For pigs and poultry three pharmaceutical forms for oral administration exist with a combination of lincomycin and spectinomycin - premixes for medicated feeding stuff, powders to be administered with the feed and powders for use in the drinking water.
Estonian: Sigade ja kodulindude jaoks on olemas linkomütsiini ja spektinomütsiini kombinatsiooni kolm suukaudset ravimvormi - ravimsööda eelsegu, söödaga manustatav pulber ja joogiveega manustatav pulber.
English: No amendments to the currently approved withdrawal periods for pigs and chicken for the aforementioned powders for use in the drinking water were considered necessary.
Estonian: Eespool nimetatud joogiveega manustatavate pulbrite praegu heakskiidetud keeluaegu sigadel ja kanadel ei peetud vajalikuks muuta.
English: On 19 May 2016, the European Medicines Agency (the Agency) completed a review of the safety and effectiveness of, and antimicrobial resistance to, veterinary medicinal products containing a combination of lincomycin and spectinomycin to be administered orally to pigs and/or poultry.
Estonian: 19. mail 2016 lõpetas Euroopa Ravimiamet (EMA) linkomütsiini ja spektinomütsiini kombinatsiooni sisaldavate, sigade ja/või kodulindude suukaudsete veterinaarravimite ohutuse ja efektiivsuse ning seonduva ravimiresistentsuse läbivaatamise.
English: Proprietary data and scientific references on efficacy and residue depletion were provided by the marketing authorisation holders in this Article 35 referral procedure.
Estonian: Müügiloa hoidjad esitasid käesolevas artikli 35 kohases esildismenetluses avaldamata andmeid ja viiteid teadusuuringutele efektiivsuse ja ravimijääkide organismist kadumise kohta.
English: Lincomycin is a lincosamide antibiotic derived from Streptomyces lincolnensis which inhibits protein synthesis.
Estonian: Linkomütsiin on linkosamiidide rühma kuuluv antibiootikum, mida eraldatakse bakterist Streptomyces lincolnensis ja mis inhibeerib valgusünteesi.
English: Lincomycin is active against gram-positive bacteria, some anaerobic gram-negative bacteria and Mycoplasma spp.
Estonian: Linkomütsiin toimib grampositiivsete bakterite, teatud anaeroobsete gramnegatiivsete bakterite ning bakterite Mycoplasma spp.